Kenvue, the company behind Tylenol and a recent spinoff from Johnson & Johnson, is facing a significant public relations crisis as President Trump and others raise concerns about unproven links between the pain reliever and autism. This situation is critical not only for Kenvue's reputation but also for consumer trust in its products, especially as it recently made its debut on the New York Stock Exchange. How Kenvue navigates this challenge could impact its future and the broader pharmaceutical industry.

Kenvue is preparing for a surge of lawsuits related to Tylenol, as concerns grow over its potential link to autism, particularly when used during pregnancy. The Trump administration has previously issued warnings about these risks, which Kenvue disputes. This situation is significant as it raises questions about the safety of widely used medications and could impact public trust in pharmaceutical companies.